canagliflozin

Home » Classic Medicine » Pharmacology » canagliflozin
canagliflozin2016-11-15T03:06:41+00:00

canagliflozin 

ENDOCRINOLOGY, PHARMACOLOGY

An agent approved for managing type 2 diabetes which reduces glucose resorption in the kidneys by inhibiting the sodium glucose co-transporter (SGLT2). Canagliflozin therapy is associated with weight loss and reduced blood pressure.

Adverse effects Fungal infections of female genital tract, urinary tract infections, increased urination. 

Proprietary name Invokana

Reference Product literature, Janssen Pharmaceuticals

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.